<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01810120</url>
  </required_header>
  <id_info>
    <org_study_id>OPBG_359.11</org_study_id>
    <nct_id>NCT01810120</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT</brief_title>
  <official_title>Phase I/II Study of Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Family Donor After TCR Alfa Beta Negative Selection in Pediatric Patients Affected by Hematological Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mariella Enoc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allocation: Non-Randomized Endpoint Classification: Safety/Feasibility Intervention Model:
      Single Group Assignment Masking: Open Label Primary Purpose: Treatment Study to assess the
      feasibility and safety of the infusion of a T cells receptor (TCR) alfa beta depleted graft
      in pediatric patients affected by malignant and non-malignant hematological disorders and
      receiving an Hematopoietic stem cell transplantation (HSCT) from a Human leukocyte antigen
      (HLA) partially matched family donor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the hypothesis is that the transplantation of Peripheral blood stem cells
      (PBSC)selectively depleted of TCR alfa beta T lymphocytes would offers some advantages over
      the use of positively selected CD34+ stem cells because of the presence of other non-stem
      ancillary cells (in particular Natural killer (NK) and alfa beta T cells) that might have
      potential positive effects on the outcome of the transplant.

      The clinical relevance of NK-cell alloreactivity has been demonstrated in adult patients
      affected by Acute myeloid leukemia (AML) and given T-cell depleted HSCT from an HLA-disparate
      relative where a subgroup of patients had a particularly low risk of leukemia relapse. These
      patients belonged to the group transplanted from a donor having NK cells that were
      alloreactive towards recipient targets i.e. the patient cells express HLA-class I alleles
      that do not share the inhibiting allelic determinants recognized by Killer
      immunoglobulin-like receptors (KIR) on donor NK cells. The emergence of this concept of
      NK-cell alloreactivity has represented a sort of revolution in the field of Haplo-identical
      hematopoietic stem cell translantation (haplo-HSCT), as the presence of alloreactive NK cells
      has been shown to positively affect the outcome of transplantation in adults and to display a
      Graft versus leukemia (GvL) effect that can compensate for the lack of T-specific anti-tumor
      effect.

      The purpose of this study is to evaluate the feasibility and safety of the selective infusion
      of TCR alfa beta T cell depleted graft in pediatric patients affected by malignant or non
      malignant hematological disorders and receiving an HSCT from a partially matched family
      donor.

      This study will provide new data on the feasibility and the safety of using a TCR alfa beta T
      cell depleted graft instead of fully T cell depleted graft to improve the outcome of patients
      receiving a haplo-HSCT for the treatment of hematological disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD34+ cells</measure>
    <time_frame>up to 3 month</time_frame>
    <description>Target number of CD34+ cells in at least 80% of the patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary and secondary graft failure</measure>
    <time_frame>up to 24 months after transplantation</time_frame>
    <description>Cumulative incidence of primary and secondary graft failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic GvHD</measure>
    <time_frame>up to 24 months after transplantation</time_frame>
    <description>Cumulative incidence and severity of acute and chronic GvHD occurring after the transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) and disease-free survival</measure>
    <time_frame>up to 24 months after transplantation</time_frame>
    <description>The overall survival (OS) and disease-free survival probability compared with a cohort of historical controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TCR alfa beta cells</measure>
    <time_frame>up to 12 months after the transplantation</time_frame>
    <description>The immunological reconstitution of TCR alfa beta cells compared with a cohort of historical controls</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Leukemia Acute Myeloid - AML</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>TCR alfa beta depleted graft, infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TCR alfa beta T cell depletion</intervention_name>
    <description>total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient</description>
    <arm_group_label>TCR alfa beta depleted graft, infusion</arm_group_label>
    <other_name>nucleated cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 3 months and &lt; 21 years

          -  Patients diagnosed with malignant hemopathies (Acute Lymphoblastic leukemia (ALL),
             Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma (NHL)) in complete morphological
             remission or Myelodysplastic Syndromes (MDS), Solid Tumors or non malignant
             hematological disorders (SCID, Acquired and Congenital Aplastic Anemia, other Primary
             Immunodeficiencies, Life-threatening Cytopenia) eligible for an allogeneic
             transplantation and lacking a related or unrelated HLA-matched donor

          -  Patients displaying an HLA-partially matched family donor

          -  Lansky/Karnofsky score &gt; 40, WHO &gt; 4

          -  Signed written informed consent

        Exclusion Criteria:

          -  Grade &gt;II acute GvHD or chronic extensive GvHD at the time of inclusion

          -  Patient receiving an immunosuppressive treatment for GvHD treatment at the time of
             inclusion

          -  Dysfunction of liver (ALT/AST &gt; 5 times normal value, or bilirubin &gt; 3 times normal
             value), or of renal function (creatinine clearance &lt; 30 ml / min)

          -  Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive
             heart failure or left ventricular ejection fraction &lt;40%)

          -  Current active infectious disease (including positive HIV serology or viral RNA)

          -  Serious concurrent uncontrolled medical disorder

          -  Pregnant or breast feeding female patient

          -  Lack of parents' informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Locatelli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bambino Gesù Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology/Hematology of the Hospital Bambino Gesù (Roma)</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006 Apr 27;354(17):1813-26. Review.</citation>
    <PMID>16641398</PMID>
  </reference>
  <reference>
    <citation>Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant. 2008 Jan;41(2):207-14. Epub 2007 Dec 17. Review.</citation>
    <PMID>18084331</PMID>
  </reference>
  <reference>
    <citation>Gluckman E. Cord blood transplantation. Biol Blood Marrow Transplant. 2006 Aug;12(8):808-12.</citation>
    <PMID>16864050</PMID>
  </reference>
  <reference>
    <citation>Locatelli F, Pende D, Maccario R, Mingari MC, Moretta A, Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol. 2009 Nov;133(2):171-8. doi: 10.1016/j.clim.2009.04.009. Epub 2009 May 29.</citation>
    <PMID>19481979</PMID>
  </reference>
  <reference>
    <citation>Martelli MF, Aversa F, Bachar-Lustig E, Velardi A, Reich-Zelicher S, Tabilio A, Gur H, Reisner Y. Transplants across human leukocyte antigen barriers. Semin Hematol. 2002 Jan;39(1):48-56. Review.</citation>
    <PMID>11799529</PMID>
  </reference>
  <reference>
    <citation>Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Cunningham-Rundles S, Dupont B, Hodes MZ, Good RA, O'Reilly RJ. Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood. 1983 Feb;61(2):341-8.</citation>
    <PMID>6217853</PMID>
  </reference>
  <reference>
    <citation>Antoine C, Müller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J, Fasth A, Heilmann C, Wulffraat N, Seger R, Blanche S, Friedrich W, Abinun M, Davies G, Bredius R, Schulz A, Landais P, Fischer A; European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003 Feb 15;361(9357):553-60.</citation>
    <PMID>12598139</PMID>
  </reference>
  <reference>
    <citation>Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995 Dec;1(12):1268-73.</citation>
    <PMID>7489407</PMID>
  </reference>
  <reference>
    <citation>Reisner Y, Martelli MF. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Immunol Today. 1999 Aug;20(8):343-7. Review.</citation>
    <PMID>10431152</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C, et al. Successful engraftment of T-cell-depleted haploidentical &quot;three-loci&quot; incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994 Dec 1;84(11):3948-55.</citation>
    <PMID>7524753</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y, Martelli MF. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998 Oct 22;339(17):1186-93.</citation>
    <PMID>9780338</PMID>
  </reference>
  <reference>
    <citation>Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, Aloisi T, Saab JP, Santucci A, Perruccio K, Martelli MP, Mecucci C, Reisner Y, Martelli MF. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005 May 20;23(15):3447-54. Epub 2005 Mar 7.</citation>
    <PMID>15753458</PMID>
  </reference>
  <reference>
    <citation>Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V; Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008 Nov 1;112(9):3574-81. doi: 10.1182/blood-2008-02-140095. Epub 2008 Jul 7.</citation>
    <PMID>18606875</PMID>
  </reference>
  <reference>
    <citation>Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V; Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood. 2010 Apr 29;115(17):3437-46. doi: 10.1182/blood-2009-03-207001. Epub 2009 Dec 29.</citation>
    <PMID>20040760</PMID>
  </reference>
  <reference>
    <citation>Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376. Review.</citation>
    <PMID>2683611</PMID>
  </reference>
  <reference>
    <citation>Moretta L, Ciccone E, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: origin, clonality, specificity, and receptors. Adv Immunol. 1994;55:341-80. Review.</citation>
    <PMID>7508176</PMID>
  </reference>
  <reference>
    <citation>Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004 Jan 28;23(2):255-9. Epub 2003 Dec 18. Review.</citation>
    <PMID>14685277</PMID>
  </reference>
  <reference>
    <citation>Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol. 2002 Jan;3(1):6-8. Review.</citation>
    <PMID>11753399</PMID>
  </reference>
  <reference>
    <citation>Moretta A, Locatelli F, Moretta L. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias. Immunol Rev. 2008 Aug;224:58-69. doi: 10.1111/j.1600-065X.2008.00651.x. Review.</citation>
    <PMID>18759920</PMID>
  </reference>
  <reference>
    <citation>Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216. Epub 2001 Oct 4. Review.</citation>
    <PMID>11861602</PMID>
  </reference>
  <reference>
    <citation>Parham P. Innate immunity: The unsung heroes. Nature. 2003 May 1;423(6935):20.</citation>
    <PMID>12721604</PMID>
  </reference>
  <reference>
    <citation>Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood. 2009 Mar 26;113(13):3119-29. doi: 10.1182/blood-2008-06-164103. Epub 2008 Oct 22.</citation>
    <PMID>18945967</PMID>
  </reference>
  <reference>
    <citation>Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009 Aug 21;31(2):184-96. doi: 10.1016/j.immuni.2009.08.006.</citation>
    <PMID>19699170</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bambino Gesù Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Mariella Enoc</investigator_full_name>
    <investigator_title>Director Department of Pediatric Hematology and Oncology</investigator_title>
  </responsible_party>
  <keyword>Hematologic</keyword>
  <keyword>Malignant</keyword>
  <keyword>Non-Malignant</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Transplant</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Acute Myeloid leukemia</keyword>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>T cells receptor alfa beta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

